Skip to content Skip to footer
Subscribe Now
Viewpoints_Dr. Volker Knappertz
VIEWPOINTS

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Shots: Volker spoke about the granting of marketing authorization by EC to treat adults with active lupus nephritis.The approval was based on the results of the P-III AURORA study  Volker also talked about the collaboration between Aurinia and Otsuka Pharmaceutical for the development and commercialization of LUPKYNIS The interview gives an understanding of how Aurinia…
December 7, 2022

Read more

Viewpoints_Neil Solomons
VIEWPOINTS

PharmaShots Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis

In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National Kidney Foundation 2021 Spring Clinical Meetings. Shots: New data analysis from the AURORA and AURA clinical studies shows that Aurinia's therapy demonstrated efficacy across all LN biopsy classes. These data show that treatment…
June 1, 2021

Read more